标题
Fibroblast growth factor receptors, developmental corruption and malignant disease
作者
关键词
-
出版物
CARCINOGENESIS
Volume 34, Issue 10, Pages 2198-2205
出版商
Oxford University Press (OUP)
发表日期
2013-07-25
DOI
10.1093/carcin/bgt254
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas
- (2013) Q. Zhao et al. CLINICAL CANCER RESEARCH
- Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
- (2013) Maria Vittoria Dieci et al. Cancer Discovery
- A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
- (2012) K. Mross et al. CLINICAL CANCER RESEARCH
- Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2012) R. S. Finn et al. CLINICAL CANCER RESEARCH
- Fibroblast Growth Factor Receptor Inhibitors
- (2012) Suneel Kumar B.V.S et al. CURRENT PHARMACEUTICAL DESIGN
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
- (2012) Niantao Deng et al. GUT
- Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status
- (2012) She-Juan An et al. PLoS One
- Selfish Spermatogonial Selection: Evidence from an Immunohistochemical Screen in Testes of Elderly Men
- (2012) Jasmine Lim et al. PLoS One
- Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
- (2012) D. Singh et al. SCIENCE
- FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
- (2012) V. Guagnano et al. Cancer Discovery
- Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2011) J.-W. Park et al. CLINICAL CANCER RESEARCH
- A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models
- (2011) G. Zhao et al. MOLECULAR CANCER THERAPEUTICS
- Targeting mutant fibroblast growth factor receptors in cancer
- (2011) Heidi Greulich et al. TRENDS IN MOLECULAR MEDICINE
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- (2011) Peter S. Hammerman et al. Cancer Discovery
- Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients
- (2010) P. M. Ellis et al. CLINICAL CANCER RESEARCH
- A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer
- (2010) Lambertus A Kiemeney et al. NATURE GENETICS
- Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression
- (2010) Kathryn E. Ware et al. PLoS One
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- (2010) J. Weiss et al. Science Translational Medicine
- Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate
- (2009) Punit H. Marathe et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Crystal Structure of a Fibroblast Growth Factor Homologous Factor (FHF) Defines a Conserved Surface on FHFs for Binding and Modulation of Voltage-gated Sodium Channels
- (2009) Regina Goetz et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- FGFR2 Abnormalities Underlie a Spectrum of Bone, Skin, and Cancer Pathologies
- (2009) Masaru Katoh JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors
- (2009) Anne Goriely et al. NATURE GENETICS
- The FGF family: biology, pathophysiology and therapy
- (2009) Andrew Beenken et al. NATURE REVIEWS DRUG DISCOVERY
- Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
- (2008) Antonis C. Antoniou et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Inhibition of Fibroblast Growth Factor 19 Reduces Tumor Growth by Modulating -Catenin Signaling
- (2008) R. Pai et al. CANCER RESEARCH
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
- (2008) H. Huynh et al. CLINICAL CANCER RESEARCH
- WNT Signaling in Stem Cell Biology and Regenerative Medicine
- (2008) Masaru Katoh CURRENT DRUG TARGETS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug-sensitive FGFR2 mutations in endometrial carcinoma
- (2008) A. Dutt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now